News & Publications

News

Deals & Cases

Stragen Pharma Group sold to ArchiMed

27 June 2021 – Stragen Pharma Group has been sold to Private equity healthcare specialist, ArchiMed through its EUR 1 billion MED Platform I fund.

Stragen Pharma is based near Geneva, Switzerland and was founded in 1990. It is a developer of hard-to-make, complex generic drugs for the treatment of patients with life-threatening conditions that require comprehensive care and monitoring, usually in intensive care units. Stragen sales of some EUR 70 million in 2020 are growing at a double-digit annual pace. Stragen’s 40 different products are sold in over 60 countries around the world, with a strong European focus.

Walder Wyss advised Stragen Pharma and its shareholders in the transaction. The team was led by Fouad G. Sayegh (Partner, Tax) and Patrick W. Vogel (Partner, Corporate/M&A) and included Yacine Rezki (Associate, Tax), Alexander Sorton (Associate, Corporate/M&A), Hugh Reeves (Managing Associate, IP) and Camille Tistounet (Trainee Lawyer).

Technically necessary cookies

Essential technical cookies are necessary for the flawless functioning of our website and cannot be disabled.
Cookies for statistics

Analytical cookies enable us to count visits and traffic sources, allowing us to measure and enhance the performance of our website. They assist us in answering questions such as which pages are the most popular, which are the least used, and how visitors navigate the website. All information collected by these cookies is aggregated and therefore anonymous.
Marketing cookies may be set by our advertising partners on our website. These companies can use them to create a profile of your interests and display relevant advertisements on other websites. They operate by uniquely identifying your browser and device. By activating these cookies, you acknowledge and consent to the information collected by such cookies being sent to providers outside of Switzerland and the EU, including countries with (from the perspective of Swiss data protection law) inadequate data protection (e.g., the United States, Singapore, and Taiwan). You also acknowledge that data transmitted abroad is no longer protected by Swiss law, and foreign laws as well as regulatory orders may require the disclosure of this data to authorities and other third parties.

Marketing cookies may be set by our advertising partners on our website. These companies can use them to create a profile of your interests and display relevant advertisements on other websites. They operate by uniquely identifying your browser and device. By activating these cookies, you acknowledge and consent to the information collected by such cookies being sent to providers outside of Switzerland and the EU, including countries with (from the perspective of Swiss data protection law) inadequate data protection (e.g., the United States, Singapore, and Taiwan). You also acknowledge that data transmitted abroad is no longer protected by Swiss law, and foreign laws as well as regulatory orders may require the disclosure of this data to authorities and other third parties.